Zaltzman, Haim

Haim Zaltzman

Partner

haim.zaltzman@lw.com
haim.zaltzman@lw.com
    Zaltzman, Haim

    Haim Zaltzman

    Partner

    haim.zaltzman@lw.com
    Top Financing Lawyers in North America

    MergerLinks FY 2020

    Ranked – Banking & Finance

    Chambers USA 2016-2022

    “Haim does an excellent job in support of our company. He is very user-friendly, is very commercial and has extensive industry and market knowledge.”

    Chambers USA 2022

    “He is exceptionally sharp and has a deep understanding of corporate law.”

    Chambers USA 2021

    Profile

    Haim Zaltzman, Chair of Latham & Watkins' San Francisco Bay Area Finance Practice, focuses on private capital, finance, and other corporate transactions, primarily in the healthcare, life sciences, and technology fields.

    Mr. Zaltzman frequently represents borrowers/issuers, sponsors, and financial institutions in private capital transactions, including:

    • Technology growth financings (venture, structured, ABL, ARR, CARR/bookings, milestone-based, Up C, SPAC-related, and other structures)
    • Direct lending transactions (private equity acquisition financings, cash-flow, ARR, CARR, liquidity, and other structures) 
    • Life sciences intellectual property monetization transactions (IP-backed debt, royalty buyout, synthetic royalty, revenue participations, R&D financings)
    • Leasing, crypto/bitcoin, securitization, and other similar asset-based transactions 
    • Structured equity, pre-IPO debt and equity financings, and similar private capital transactions

    Mr. Zaltzman holds leadership positions with the Chinese American International School and the American Jewish Committee. 

    Mr. Zaltzman has also been featured on CNBC, The Information, Bloomberg, The Washington Post, CFO Magazine, The Recorder, Law360.com, The Daily Journal, the International Financial Law Review, and VCExperts.com for his debt experience.

    Experience

    Mr. Zaltzman's representative transactions include:

    • Hundreds of growth companies and their sponsors in every kind of financing
    • Multiple direct lenders and investors in the life sciences space, including venture, structured, royalty, and other IP-related financings
    • Various investors in late stage, growth capital, including pre-IPO converts, SPAC financings, redeemable and non-redeemable preferred, SPAC-related structures, and other secured and unsecured financings, to technology companies 
    • Various private equity and venture capital firms in debt and equity financings of all types
    • Multiple technology and life sciences companies and sponsors in deSPAC transactions 
    • Multiple lenders and companies in securitization-related transactions

    Prior Professional Experience

    • Former Editor of the Stanford Journal of International Relations
    • Fulbright Scholar in Russia
    • Prior to Latham & Watkins, attorney in the New York office of Skadden, Arps, Slate, Meagher & Flom LLP

    Thought Leadership

    • Extending Your Reach: New Approaches to Values-Based Compliance and Contracting, January 5, 2023
    • Emerging Growth Debt, Venture Capital General Counsel Meeting, Boulder, Colorado, March 29-30, 2017
    • Financing Emerging Growth Companies with Debt, Webcast, May 4, 2017
    • The Healthcare & Technology Industries’ Burgeoning Emerging Growth Debt Market, March 13, 2015
    • When Venture Funding is Debt, Not Equity, June 22, 2011
    • After the Credit Crunch: Venture Credit Facilities at the Term Sheet Stage, June 20, 2011

    Qualifications

    Bar Qualification

    • California
    • New York

    Education

    • BA, Stanford University
    • JD, Harvard Law School
    • MA, Russian Academy of Sciences

    Languages Spoken

    • English
    • Hebrew
    • Russian

    Practices

    Industries

    Recognition

    Read More

    News & Insights

    Read More